Pre-eclampsia is a hypertensive disorder complicating 5-8% of pregnancies [1]. It is characterized by hypertension and proteinuria and is a leading cause of maternal mortality in 15-20% of pregnant women in developed countries versus 40-80% in developing countries [2,3]. Pre-eclampsia is a state of angiogenic imbalance associated with endothelial dysfunction within specifi c vascular beds (4). The abnormalities in the development of the placental vasculature could occur early, weeks to months before the development of the clinical manifestations of pre-eclampsia [5]. Placental growth factor (PlGF), a member of the vascular endothelial growth factor (VEGF) family, is one of the main factors that play a key role in the remodeling process of maternal arteries in normal pregnancy. This growth factor is released into the bloodstream by the migrating trophoblasts [6]. The soluble fms-like tyrosine kinase-1 (sFlt-1), also known as soluble VEGF receptor-1, is a variant of the VEGF receptor, which is secreted from endothelial cells, monocytes, and placenta. The sFlt-1 is capable of binding with both VEGF and PlGF, consequently regulating their action [7]. Alterations in maternal serum concentrations of PlGF and sFlt-1 have been reported to precede the onset of clinically identifi able preeclampsia as early as the fi rst trimester [6]. The aim of our study is to assess the clinical utility of PlGF and sFlt-1 as early predictors of preeclampsia.